Plamotamab is under clinical development by Xencor and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Plamotamab’s likelihood of approval (LoA) and phase transition for Follicular Lymphoma took place on 13 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Plamotamab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Plamotamab (XmAb-13676) is under development for the treatment of B cell malignancies such as Richter's transformation, relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, relapsed and refractory Chronic Lymphocytic Leukemia, splenic marginal zone B-Cell Lymphoma extranodal marginal zone B-Cell Lymphoma, mantle cell lymphoma, Marginal Zone B-Cell Lymphoma, nodal marginal zone B-Cell Lymphoma and non B-cell chronic lymphocytic leukemia. It is administered intravenously. The drug candidate is a bi-specific monoclonal antibody that targets tumor antigen binding domain CD20 and cytotoxic T-cell CD3 binding domain. The drug candidate development is based on XmAb bi-specific antibody engineering technology.
Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.
Quick View Plamotamab LOA Data
|Highest Development Stage|